ClinicalTrials.Veeva

Find clinical trials for Chronic Lymphocytic Leukemia in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia trials near Montréal, QC, CAN:

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma....

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Obinutuzumab

Phase 1

Celgene
Celgene

Montreal, Quebec, Canada and 14 other locations

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Obinutuzumab
Drug: Venetoclax

Phase 3

Janssen
Janssen

Montreal, Quebec, Canada and 85 other locations

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Montreal, Quebec, Canada and 196 other locations

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Lymphoma, Non Hodgkin
Drug: BTCT4465A (Mosunetuzumab) IV
Drug: BTCT4465A (Mosunetuzumab) SC

Phase 1, Phase 2

Genentech
Genentech

Montréal, Quebec, Canada and 48 other locations

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

Acerta Pharma
Acerta Pharma

Montreal, Quebec, Canada and 170 other locations

venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medic...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

Roche
Roche

Montreal, Quebec, Canada and 136 other locations

the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Idelalisib
Drug: Acalabrutinib (ACP-196)

Phase 3

Acerta Pharma
Acerta Pharma

Montreal, Canada and 156 other locations

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...

Enrolling
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
T-cell Lymphoma
Drug: PRT2527
Drug: Zanubrutinib

Phase 1

Prelude Therapeutics

Montreal, Quebec, Canada and 22 other locations

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Invitation-only
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Ibrutinib

Phase 3

Janssen
Janssen

Montreal, Quebec, Canada and 172 other locations

transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also eval...

Enrolling
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Biological: Zilovertamab vedotin
Drug: Nemtabrutinib

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Montreal, Quebec, Canada and 100 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems